Sign up
Pharma Capital

RedHill BioPharma lead drug making its way towards FDA approval

RedHill Biopharma (NASDAQ:RDHL) CEO Dror Ben-Asher sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

The biopharmaceutical company is primarily focused on the development and commercialization of late clinical-stage, proprietary drugs for the treatment of gastrointestinal diseases.

 

View full RDHL profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.